This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hyung, W. J. Articles by Noh, S. H. Search for Related Content PubMed PubMed Citation Articles by Hyung, W. J. Articles by Noh, S. H. Related Collections Prognostic factors

Prognostic Impact of Lymphatic and/or Blood Vessel Invasion in Patients With Node-Negative Advanced Gastric Cancer

From the Department of Surgery (WJH, JHL, SHC, JSM, SHN), the Cancer Metastasis Research Center (WHJ, JHL, SHN), and Brain Korea 21 Project for Medical Science (JHL, SHN), Yonsei University College of Medicine, Seoul, Korea.

Correspondence: Address correspondence and reprint requests to: Sung Hoon Noh, MD, Department of Surgery, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-ku, Seoul, Korea; Fax: 82-2-313-8289; E-mail: sunghoonn{at}yumc.yonsei.ac.kr

Background: Heterogeneous survival rates in patients with similar clinicopathologic characteristics or molecular prognostic markers have been noted. This study was conducted to evaluate the prognostic effect of lymphatic and/or blood vessel invasion (LBVI), identified by routine hematoxylin and eosin staining, on the outcome of patients with node-negative advanced gastric cancer.

Methods: A total of 280 patients who underwent curative gastrectomy for advanced gastric cancer without lymph node metastasis were retrospectively reviewed. Univariate and multivariate analyses of the clinicopathological features, recurrences, and prognoses of patients with and without LBVI were performed.

Results: Lymphatic vessel invasion (LVI) was noted in 20.0%, blood vessel invasion (BVI) in 5.4%, and either LVI or BVI in 22.5%. None of the clinicopathologic features was related to LBVI. Patients with LBVI had a recurrence rate of 26.8%, whereas patients without LBVI had a recurrence rate of 13.5% (P = .018). The 5-year survival rates were 82.4% for patients without LBVI and 67.1% for patients with LBVI (P = .0222). LBVI was shown to be an independent risk factor for recurrence (relative risk, 2.30; 95% confidence interval, 1.06–4.99) and poor prognosis (relative risk, 1.88; 95% confidence interval, 1.07–3.29).

Conclusions: LBVI is an adverse prognostic indicator and the presence of LBVI seems to provide useful information for the prognosis and clinical management of patients with node-negative advanced gastric carcinoma.

Key Words: Gastric cancer • Prognosis • Lymphatic invasion • Blood vessel invasion

This article has been cited by other articles:

				S A Pritchard Best practice in macroscopic examination of gastric resections J. Clin. Pathol., February 1, 2008; 61(2): 172 - 178. [Abstract] [Full Text] [PDF]

				J. E. Gervasoni Jr., S. Sbayi, and B. Cady Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann. Surg. Oncol., September 1, 2007; 14(9): 2443 - 2462. [Abstract] [Full Text] [PDF]

				B.J. Dicken, L.D. Saunders, G.S. Jhangri, C. de Gara, C. Cass, S. Andrews, and S.M. Hamilton Gastric Cancer: Establishing Predictors of Biologic Behavior with Use of Population-Based Data Ann. Surg. Oncol., June 1, 2004; 11(6): 629 - 635. [Abstract] [Full Text] [PDF]